Compare IDEXX Laboratories, Inc. (IDXX) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Innodata Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Innodata Inc trades at $62.2 (market cap $2.10B). The key difference: IDEXX Laboratories, Inc. is far larger — about 19.3× Innodata Inc's market cap, and Innodata Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Innodata Inc for 19 Days on average.
| IDXX | INOD | |
|---|---|---|
Market Cap | $40.43B | $2.10B |
Volume | 692,164 | 989,493 |
Sector | Health | Technology |
52-Week High | $766.68 | $121.50 |
52-Week Low | $504.70 | $34.45 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | $41.32B | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
INOD trades at $61.54, down 2.96% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consecutive earnings beats, with Q1 2026 EPS of $0.42 significantly exceeding the $0.13 estimate, and demonstrated robust revenue growth from $252M in 2025 to $317M projected for 2026. Analyst sentiment remains positive with a 67% buy rating, though the stock faces valuation concerns with a P/E of 47.4.
The outlook for INOD is mixed: strong AI-driven revenue growth and expanding margins support upside potential, but high valuation multiples and bearish technical signals present near-term risks. Investor focus should remain on execution of new initiatives like the motion-capture AI lab and customer diversification efforts to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
